So Glad You Asked Podcast: Sheehan Fisher, PhD on Partners’ Mental Health
Partners’ mental health is often overlooked in the perinatal period. Dr. Sheehan Fisher discusses why supporting all parents improves outcomes for families.
Pharmacologic Treatment of Postpartum Depression: What Happens in the Real World?
New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
Is There a Link Between Endometriosis and Perinatal Depression?
Emerging data suggest women with endometriosis face a higher risk of postpartum depression and anxiety, underscoring the need for proactive screening and individualized care.
Can Esketamine Be Used to Prevent Postpartum Depression?
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Beyond the FDA Panel: Medical Experts Reaffirm the Safety and Essential Role of SSRIs for Perinatal Mental Health
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; however, medical organizations and experts support the important role of SSRIs and other medications in supporting maternal mental health.
Unraveling the Complexities of Perinatal Suicide: Insights from Women’s Lived Experiences
This study uncovers how trauma, isolation, loss of identity, and lack of support can overlap and amplify each other, deepening despair and driving suicide risk among women in the perinatal period.
Marlene Freeman, MD: Getting to the Truth About SSRIs and Pregnancy (Video)
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
Information for Patients: How to Interpret the Recent FDA Panel on SSRIs and Pregnancy
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â
Zuranolone and Breastfeeding: Emerging Data and Clinical Implications
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
Weighing the Evidence: Response to the FDA’s Recent Panel on Antidepressant Use in Pregnancy.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy but ignored or diminished the risks associated with untreated depression in the mother.Â